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More studies are needed to determine which exercise
programmes for intermittent claudication should be
funded.
We read with interest the editorial by Popplewell and
Bradbury.1 Treatment of claudicants aims at improving
health related quality of life (HRQoL) by improved daily-life
walking. Treadmill walking distance but not HRQoL improves
more with, for example, hospital based supervised exercise
programmes (SEP) than with unsupervised exercise pro-
grammes (UEP). Treadmill walking, the primary outcome in
many studies, is also used as training modality in many SEPs
but not in UEPs or home based (HEP) supervised exercise
programmes, introducing a risk of bias. Moreover, the
outcome treadmill walking is questioned and daily-life
walking (GPS monitored) or corridor tests (e.g. 6 minute
walk test, 6MWT) correlate better to HRQoL.2 Many clau-
dicants dislike prolonged training programmes and compli-
ance to SEP may be only 20e40% at 1 year.3 We identiﬁed
seven randomized and two non-randomized controlled tri-
als in a recently submitted systematic review (unpublished)
evaluating HEP compared with SEP or UEP. HEP and UEP
were inferior to SEP regarding treadmill walking whereas
HEP improved the 6MWT compared with UEP and SEP.
Hence, although SEP improves treadmill walking, the
generalizability to claudicants in general may be uncertain
and the links to improved daily-life walking and HRQoL
unclear. We agree that further RCTs are required and sug-
gest these should include 12 month follow up, HRQoL,
and “daily-life” walk tests. We have started such a study
comparing SEP, HEP, and UEP (SUNFIT Trial, ClinicalTrials.gov
NCT02341716) and hopefully further studies will be initi-
ated. We believe they are needed.
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We would like to thank the authors of the SUNFIT trial for
their input on this important issue in response to our recent
editorial on this subject.1 We agree that good quality evi-
dence surrounding patient-centred outcomes such as
health-related quality of life is missing in the current liter-
ature, with too many studies focusing on multiple “perfor-
mance”-related outcomes such as maximal walking distance
and treadmill walking.
Hopefully the upcoming SUNFIT trial will shed some light
on which intervention, if any, provides a more long-term,
clinical, and cost-effective therapy for our patients with
intermittent claudication, vital evidence that the National
Institute for Health Care and Excellence called for in the
published Clinical Guideline 147.2 We would also advocate
the need for such a study in the UK to help advise patients,
clinicians, and healthcare providers.
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Analyzing the Role of Systematic Pre-operative Coronary
Angiography before Elective Carotid Endarterectomy in
Patients with Asymptomatic Coronary Artery Disease’
We read with great interest the results of the study by
Illuminati et al. regarding the predictive role of pre-
operative coronary angiography before carotid endarterec-
tomy (CEA) in patients with asymptomatic coronary artery
disease (CAD).1 These results also concur with their previ-
ously published results regarding early post-operative out-
comes.2 However, there are some interesting points that
should be commented on.
Firstly, the group of patients who had not undergone a
percutaneous coronary intervention (PCI) pre-operatively
underwent CEA under single antiplatelet protection
(aspirin), while the rest of the patients underwent CEA under
dual antiplatelet protection (aspirin and clopidogrel) after
undergoing PCI. Additionally, the ﬁrst group showed a much
higher incidence of myocardial infarctions (MIs) after CEA
compared with the second group. But was this the effect of
PCI itself or the effect of dual antiplatelet coverage? Have the
authors considered that this could interfere with their results
or produce potential bias? According to recent data, dual
antiplatelet treatment reduces adverse cardiovascular out-
comes after PCI by almost 20% comparedwith aspirin alone,3
and also leads to a reduction of stent thrombosis after PCI.4
Secondly, the authors report that one MI was observed
after a PCI re-stenosis. However, in the “Results” section,
among all complications of PCI, the re-stenosis rate is not
included in the secondary outcomes. In our view, it would be
essential that the number of all asymptomatic re-stenoses
after PCI that occurred during the study period should be
reported. The presence of carotid artery disease alone has
been associated with an increased risk for re-stenosis after
PCI, justifying the reporting of such results.5 Finally, re-
stenosis remains an important adverse outcome after coro-
nary angioplasty or stenting that may lead to cardiac com-
plications or even necessitate a re-intervention.
Finally, regarding adverse cardiac events, another impor-
tant issue is the designation of post-operative monitoring in
patients undergoing CEA. In this trial, the authors state that
they monitored patients during the ﬁrst day after PCI, uti-
lizing troponinmeasurements and electrocardiography (ECG)
evaluation. But what exactly happened after CEA? Nine MIs
were reportedwithin 1month of CEA in patients without pre-
operative coronary angiography, although the exact moni-
toring protocol or the distribution of these events in the ﬁrst
days post-operatively is missing. Is this not essential fordesigning proper post-operative management? Recently, we
have investigated the incidence of myocardial ischemia after
CEA in different cardiac risk patients. In our cohort of 324
patients undergoing CEA, 44 presented with asymptomatic
myocardial ischemia on the ﬁrst and third post-operative
days, independently from cardiac risk, and this was also
associated with late cardiac events.6 Previously, we have also
estimated that the incidence of cardiac damage on the third
day post-operatively reached almost 10% of the total of
cardiac events post-CEA.7 Therefore, a standardized moni-
toring of patients after CEA, including serum biomarker
measurement and ECG evaluation, until at least the third
post-operative day would, perhaps, be of more beneﬁt.
REFERENCES
1 Illuminati G, Schneider F, Greco C, Mangieri E, Schiariti M,
Tanzilli G, et al. Long-term results of a randomized controlled
trial analyzing the role of systematic pre-operative coronary
angiography before elective carotid endarterectomy in patients
with asymptomatic coronary artery disease. Eur J Vasc Endovasc
Surg 2015;49:366e74.
2 Illuminati G, Ricco JB, Greco C, Mangieri E, Calio’ F, Ceccanei G,
et al. Systematic pre-operative coronary angiography and stenting
improves post-operative results of carotid endarterectomy in
patients with asymptomatic coronary artery disease: a rando-
mised controlled trial. Eur J Vasc Endovasc Surg 2010;39:139e45.
3 Angiolillo DJ. Variability in responsiveness to oral antiplatelet
therapy. Am J Cardiol 2009;103:27Ae34A.
4 Hirsh J, Bhatt DL. Comparative beneﬁts of clopidogrel and
aspirin in high risk patient populations: lessons from the CAPRIE
and CURE studies. Arch Intern Med 2004;164:2106e10.
5 Novo G, Maniglia D, Corrado E, Muratori I, Sutera F, Evola S,
et al. Peripheral atherosclerosis is associated with the occur-
rence of restenosis after percutaneous coronary intervention.
Coron Artery Dis 2007;18:627e31.
6 Galyfos G, Tsiouﬁs C, Theodorou D, Katsaragakis S, Zografos G,
Filis K. Cardiac troponin I after carotid endarterectomy in different
cardiac risk patients. J Stroke Cerebrovasc Dis 2015;24:711e7.
7 Galyfos G, Sigala F, Tsiouﬁs K, Bakoyiannis C, Lagoudiannakis E,
Manouras A, et al. Post-operative cardiac damage after stan-
dardized carotid endarterectomy procedures in low- and high
risk patients. Ann Vasc Surg 2013;27:433e40.G. Galyfos*, F. Sigala
First Department of Propaedeutic Surgery, University of
Athens Medical School, Hippocration Hospital, Athens,
Greece
K. Aggeli
First Department of Cardiology, University of Athens
Medical School, Hippocration Hospital, Athens, Greece
K. Filis
First Department of Propaedeutic Surgery, University of
Athens Medical School, Hippocration Hospital, Athens,
Greece
*Corresponding author.
Email-address: georgegalyfos@hotmail.com (G. Galyfos)
